XTXXFOTCPharmaceutical PreparationsFiscal year ends December 31
Adastra Holdings Ltd.
Financials through fiscal 2022, year ended Dec 31, 2022Last filing: 20-F on May 17, 2023
$0.01+0.00 (0.00%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2020 to 2022
Gross margin
46.0%
Operating margin
-6.0%
Growth rates
Compound annual growth to fiscal 2022
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +136.2% | – | – | – | |
| Gross profit | +214.5% | – | – | – |
Returns and balance sheet
3 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2022 | Trend |
|---|---|---|---|---|
| Current ratio | 1.03 | 1.03 | 0.71 | |
| Interest coverage | -17.9× | -17.9× | -2.3× | |
| Inventory turnover | – | – | 2.5× | |
| Capex to revenue | 73.1% | 73.1% | 4.7% | |
| Diluted shares | 40M | 40M | 59M |
Cash use needs five years of cash flow figures
Adastra does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2022 against fiscal 2021
3of 5 tests passed in fiscal 2022. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zeroC$1.32M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net incomeC$1.32M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.79 → 0.71
- No dilutionShare count did not rise50M → 59M
- Gross margin improvedGross margin up on the prior year34.53% → 45.97%
- More efficientAsset turnover rose0.41 → 0.46